Free Trial

BridgeBio Pharma (BBIO) Stock Forecast & Price Target

BridgeBio Pharma logo
$43.18 -1.68 (-3.74%)
As of 04:00 PM Eastern

BridgeBio Pharma - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
13

Based on 14 Wall Street analysts who have issued ratings for BridgeBio Pharma in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 1 has given a hold rating, and 13 have given a buy rating for BBIO.

Consensus Price Target

$58.85
36.28% Upside
According to the 14 analysts' twelve-month price targets for BridgeBio Pharma, the average price target is $58.85. The highest price target for BBIO is $95.00, while the lowest price target for BBIO is $46.00. The average price target represents a forecasted upside of 36.28% from the current price of $43.18.
Get the Latest News and Ratings for BBIO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BridgeBio Pharma and its competitors.

Sign Up

BBIO Analyst Ratings Over Time

TypeCurrent Forecast
6/30/24 to 6/30/25
1 Month Ago
5/31/24 to 5/31/25
3 Months Ago
4/1/24 to 4/1/25
1 Year Ago
7/1/23 to 6/30/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
13 Buy rating(s)
11 Buy rating(s)
11 Buy rating(s)
10 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$58.85$57.09$52.64$47.21
Forecasted Upside36.28% Upside66.01% Upside59.41% Upside86.40% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

BBIO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BBIO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

BridgeBio Pharma Stock vs. The Competition

TypeBridgeBio PharmaMedical CompaniesS&P 500
Consensus Rating Score
2.92
2.81
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside32.01% Upside8,873.84% Upside12.50% Upside
News Sentiment Rating
Positive News

See Recent BBIO News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/30/2025Wells Fargo & Company
3 of 5 stars
Tiago Fauth
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$67.00 ➝ $76.00+71.77%
6/25/2025Bank of America
4 of 5 stars
Geoff Meacham
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$50.00 ➝ $54.00+20.58%
6/17/2025Wolfe Research
4 of 5 stars
Andy Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$49.00+19.11%
6/9/2025HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Raghuram Selvaraju
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$53.00 ➝ $56.00+45.00%
4/30/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Biren Amin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$46.00 ➝ $63.00+63.64%
4/30/2025Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Greg Harrison
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetSector Outperform ➝ Sector Outperform$52.00 ➝ $55.00+42.86%
4/30/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Eliana Merle
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$65.00 ➝ $72.00+86.66%
3/31/2025Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Joshua Smith
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$50.00+42.41%
3/24/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Anupam Rama
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$44.00 ➝ $50.00+43.80%
2/21/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Lebowitz
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$45.00 ➝ $49.00+32.87%
2/21/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Josh Schimmer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$95.00 ➝ $95.00+156.27%
12/23/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$45.00 ➝ $50.00+82.02%
10/17/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$47.00 ➝ $46.00+76.86%
10/3/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform
3/21/2024Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$45.00+57.18%
3/5/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$60.00 ➝ $53.00+63.81%
1/31/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$37.00+2.52%
7/18/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$29.00 ➝ $50.00+56.05%
7/18/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$32.00 ➝ $42.00+31.09%
7/17/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$24.00 ➝ $33.00+3.00%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 04:59 PM ET.


BBIO Forecast - Frequently Asked Questions

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for BridgeBio Pharma is $58.85, with a high forecast of $95.00 and a low forecast of $46.00.

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BridgeBio Pharma in the last year. There is currently 1 hold rating and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BBIO shares.

According to analysts, BridgeBio Pharma's stock has a predicted upside of 36.28% based on their 12-month stock forecasts.

BridgeBio Pharma has been rated by research analysts at Bank of America, HC Wainwright, Piper Sandler, Scotiabank, UBS Group, Wells Fargo & Company, and Wolfe Research in the past 90 days.

Analysts like BridgeBio Pharma more than other "medical" companies. The consensus rating score for BridgeBio Pharma is 2.93 while the average consensus rating score for "medical" companies is 2.81. Learn more on how BBIO compares to other companies.


This page (NASDAQ:BBIO) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners